PURPOSE: The purpose of the study was to investigate the impact of a family history (FH) of colorectal cancer (CRC) in first-degree relatives on the outcome of patients with CRC in a veterans' hospital in Taiwan. METHODS: Patients (N = 3,383) with colorectal adenocarcinoma were studied; pedigrees were collected prospectively. Associations between FH and clinicopathologic variables were analyzed using linear-by-linear association. Survival was examined with Kaplan-Meier curves and the log-rank test. RESULTS: Two hundred ninety-seven patients (8.78%) had a first-degree relative with CRC. The average age of onset of CRC was 68.3 years in patients without a FH. This was significantly higher than the age of onset in patients with a FH (66.4 years--one first-degree relative with CRC; 48.8 years--two or more first-degree relatives, P < 0.001). Patients with more affected family members had a higher incidence of right-sided tumor (P = 0.004), metachronous cancer (P = 0.034), and less-advanced disease (P = 0.044). The 5-year overall survival was 83% for patients with two or more first-degree relatives with CRC, 57% for those with one first-degree relative, and 55% for those without a FH (P = 0.001). The 5-year DFS was 91% for patients with two or more first-degree relatives, 66% for those with one first-degree relative, and 64% for those without a FH of CRC (P = 0.002). In the multivariate analysis, TNM stage played the most independent prognostic factor, followed by FH (P < 0.001, hazard ratio = 1.52; 95% confidence interval, 1.24-1.85). CONCLUSIONS: CRC patients with a family history of CRC had better survival than did those without a family history of CRC.
PURPOSE: The purpose of the study was to investigate the impact of a family history (FH) of colorectal cancer (CRC) in first-degree relatives on the outcome of patients with CRC in a veterans' hospital in Taiwan. METHODS:Patients (N = 3,383) with colorectal adenocarcinoma were studied; pedigrees were collected prospectively. Associations between FH and clinicopathologic variables were analyzed using linear-by-linear association. Survival was examined with Kaplan-Meier curves and the log-rank test. RESULTS: Two hundred ninety-seven patients (8.78%) had a first-degree relative with CRC. The average age of onset of CRC was 68.3 years in patients without a FH. This was significantly higher than the age of onset in patients with a FH (66.4 years--one first-degree relative with CRC; 48.8 years--two or more first-degree relatives, P < 0.001). Patients with more affected family members had a higher incidence of right-sided tumor (P = 0.004), metachronous cancer (P = 0.034), and less-advanced disease (P = 0.044). The 5-year overall survival was 83% for patients with two or more first-degree relatives with CRC, 57% for those with one first-degree relative, and 55% for those without a FH (P = 0.001). The 5-year DFS was 91% for patients with two or more first-degree relatives, 66% for those with one first-degree relative, and 64% for those without a FH of CRC (P = 0.002). In the multivariate analysis, TNM stage played the most independent prognostic factor, followed by FH (P < 0.001, hazard ratio = 1.52; 95% confidence interval, 1.24-1.85). CONCLUSIONS: CRC patients with a family history of CRC had better survival than did those without a family history of CRC.
Authors: C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Jennifer A Chan; Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Paul Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Robert S Warren; Monica Bertagnolli; Charles S Fuchs Journal: JAMA Date: 2008-06-04 Impact factor: 56.272
Authors: Nora B Henrikson; Elizabeth M Webber; Katrina A Goddard; Aaron Scrol; Margaret Piper; Marc S Williams; Doris T Zallen; Ned Calonge; Theodore G Ganiats; A Cecile J W Janssens; Ann Zauber; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Evelyn P Whitlock Journal: Genet Med Date: 2015-01-15 Impact factor: 8.822
Authors: Lieke Egbers; Anne J Grotenhuis; Katja K Aben; J Alfred Witjes; Lambertus A Kiemeney; Sita H Vermeulen Journal: Int J Cancer Date: 2014-07-09 Impact factor: 7.396
Authors: E J A Morris; S Penegar; L E Whitehouse; P Quirke; P Finan; D T Bishop; J Wilkinson; R S Houlston Journal: Br J Cancer Date: 2013-03-19 Impact factor: 7.640
Authors: Dawn Q Chong; Barbara L Banbury; Amanda I Phipps; Xinwei Hua; Jonathan Kocarnik; Ulrike Peters; Sonja I Berndt; Wen-Yi Huang; John D Potter; Martha L Slattery; Emily White; Peter T Campbell; Tabitha Harrison; Polly A Newcomb; Andrew T Chan Journal: Cancer Med Date: 2018-03-26 Impact factor: 4.452